RECEIVED CENTRAL FAX CENTER JUN 2 0 2008

In the claims:

Claim 1 (currently amended) A pharmaceutical composition for the treatment of urinary incontinence rectal or vaginal administration comprising oxybutynin as active ingredient, in combination or not with a moderated estrogen and a pharmaceutically acceptable excipient intended for vaginal or rectal administration dissolved or dispersed in a fatty material formed by semi synthetic glycerides and at least one suspension agent.

Claim 2 (currently amended) A The pharmaccutical composition of claim 1, wherein oxybutynin is selected from the group consisting of oxybutynin base, its addition salts with a mineral or organic acid and their epimers.

Cancel Claim 3.

Claim 4 (currently amended) A The pharmaceutical composition of claim 1, wherein it is selected from the form consisting of suppositories, vaginal capsules, rectal capsules and vaginal gels.

Claim 5 (currently amended)

A The pharmaceutical composition of claim 1 wherein it_contains from 1 to 25 mg of oxybutypin or its salts.

Claim 6 (currently amended) A The pharmaceutical composition of claim 5, wherein it contains from 5 to 15 mg of oxybutynin hydrochloride.

Cancel Claim 7 to 9.

Claim 10 (currently amended)

A The pharmaceutical composition of claim 1 wherein it contains one or more suspension agents.

Claim 11 (currently amended)

A The pharmaceutical composition of claim 10, wherein the suspension agent or agents are bioadhesive silicic acid derivatives.

Claim 12 (currently amended) A The pharmaceutical composition of claim 1 wherein the excipient is a fatty phase formed by semisynthetic glycerides.

Claim 13 (currently amended)

A The pharmaceutical composition of claim 11 12, wherein the semisynthetic glycerides are Witepsol® WITEPSOL® or Supposire® SUPPOCIRE®

Claim 14 (currently amended) A The pharmaceutical composition of claim 1 which also contains at least one or more gelling agents agent.

JUN 2 0 2008

Claim 15 (currently amended) A The pharmaceutical composition of claim 14, wherein the gelling agent or agents are cellulose derivatives.

Claim 16 (currently amended) A The pharmaceutical composition of claim 14, wherein the gelling agent is a carbomer.

Claim 17 (currently amended) A The pharmaceutical composition of claim 16, wherein the gelling agent is polycarbophil in acid form or in salified form.

Claim 18 (currently amended) A The pharmaceutical composition of claim 16 wherein the gelling agent is polycarbophil in the form of calcium salt.

Claim 19 (currently amended) A The pharmaceutical composition of claim 1 having a sustained release of the active ingredients, spread over more than twenty four hours, wherein the excipient is a fatty material in which the oxybutynin hydrochloride is placed in suspension.

Claim 20 (currently amended) A The pharmaceutical composition of claim 1, allowing T maxs of oxybutynin to be obtained between approximately two hours and approximately sixteen hours wherein the excipient or the vehicle is selected so that the speed of release is as long as possible.

Claim 21 (currently amended) A The pharmaceutical composition of claim 1 wherein the excipient or the vehicle is selected so that the administration of oxybutynin takes place once, or optionally twice, per twenty four hours.

Claim 22 (previously presented) A method of treating urinary incontinency in humans comprising administrating to humans in need thereof an amount of a composition of claim 1 sufficient to treat urinary incontinency.

Please add the following claims:

Claim 23 (new) The pharmaceutical composition of claim 1 also containing an estrogen selected from the group consisting of estriol, estradiol and ethers, esters and mixed esters thereof.

Claim 24 (new) The pharmaceutical composition of claim 1 containing a gelling agent.

Claim 25 (new) The pharmaceutical composition of claim 1, containing 5 to 15 mg of oxybutynin hydrochloride.

Claim 26 (new) The pharmaceutical composition of claim 1, containing 0.01 to 5 mg of little resorbed moderated estrogen.

Claim 27 (new) The pharmaceutical composition of claim 1, wherein the moderated estrogen is estriol at a dose of 0.1 to 2 mg.

Claim 28 (new) The pharmaceutical composition of claim 23, wherein the composition contains 0.2 to 1 mg of estriol.

Claim 29 (new) The pharmaceutical composition of claim 1, wherein the oxybutynyl is released from two to about sixteen hours after administration and that amount or released oxybutynin is still perceivable after thirty six hours.

Claim 30 (new) A method for alleviating the disturbances caused by urinary incontinence in adults suffering from urinary incontinence comprising administering vaginally or rectally a small but efficient amount of oxybutynin optionally in combination with a moderated estrogen to said patient.

Claim 31 (new) A method for alleviating the disturbances caused by urinary incontinence wherein the C max of oxybutynin are obtained after a period of approximately two hours to approximately sixteen hours and obtain a rate of release as extended as possible.